Midwest Financial Group’s Recursion Pharmaceuticals RXRX Stock Holding History

Midwest Financial Group’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$31.1K	Hold	10,135	–	–	0.01%	126
2025 Q4	$41.5K	Hold	10,135	–	–	0.02%	123
2025 Q3	$49.5K	Sell	10,135 -1,884	-16%	-$9.89K	0.02%	121
2025 Q2	$60.8K	Hold	12,019	–	–	0.03%	114
2025 Q1	$63.6K	Hold	12,019	–	–	0.04%	108
2024 Q4	$81.2K	Hold	12,019	–	–	0.05%	111
2024 Q3	$79K	Hold	12,019	–	–	0.05%	109
2024 Q2	$90K	Buy	+12,019	New	+$105K	0.06%	105

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Midwest Financial Group's RXRX Position: Q1 2026 in Review

Midwest Financial Group held its Recursion Pharmaceuticals (RXRX) position steady in Q1 2026 at 10,135 shares worth $31.1K. The position accounts for 0.01% of the portfolio, ranked #126.

Midwest Financial Group first reported a position in RXRX in Q2 2024 and has held it in 8 quarters since. The position peaked at $90K in Q2 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Midwest Financial Group held 10,135 shares of Recursion Pharmaceuticals worth $31.1K as of Q1 2026.
Midwest Financial Group left its Recursion Pharmaceuticals share count unchanged in Q1 2026.
Recursion Pharmaceuticals made up 0.01% of Midwest Financial Group's portfolio in Q1 2026, its #126 holding.
Midwest Financial Group first reported a position in Recursion Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
Midwest Financial Group's Recursion Pharmaceuticals position peaked at $90K in Q2 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Midwest Financial Group's 13F filing for Q1 2026, filed 22 Apr 2026.